Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Historical Acquisition Tree
Alternative names
amantadine (symmetrel) (2018)
desvenlafaxine (pristiq) (2013)
donepezil (aricept) (2016)
hydromorphone (diladid) (2016)
icosapent ethyl (vascepa) (2014)
methylphenidate (ritalin) (2022)
nifedipine (procardia) (2005)
omega-3 fatty acids (Omacor) (2014)
oxybutynin (ditropan) (2009)
oxymetazoline (ocuclear) (2020)
sufentanil (2018)
venlafaxine (effexor) (2008)
amantadine (symmetrel) (2 trials)
arbaclofen (6 trials)
baclofen (lioresal) (1 trial)
oxymetazoline (ocuclear) (4 trials)
carbidopa (sinemet) (1 trial)
levodopa (larodopa) (1 trial)
Key: Osmotica Pharmaceutical (0) Acquired (1)
revacept (1 trial)
Blepharoptosis (Phase 3)
Dyskinesias (Phase 3)
Multiple Sclerosis (Phase 3)
Muscle Spasticity (Phase 3)
Parkinson Disease (Phase 3)
Sclerosis (Phase 3)
Trials (14 total)
Trial APIs (7 total)